As mentioned above, the dopamine receptor antagonist ropinirole prevented ALS pathology in iPSC-derived motor neurons from fALS patients with TDP-43 (M337V or Q343R) mutations, and similarly, ropinirole prevented neurite regression, stress granule formation, FUS aggregation, and prevented cell death in iPSC-derived motor neurons from fALS patients with FUS (H517D) mutations (Fujimori et al., 2018). Here, FUS is linked to amyotrophic lateral sclerosis.